Cingulate (CING)
Develops once-daily ADHD medicines using a multi-core timed-release platform.
Something off on this page? Send us feedback.
Its lead candidate, CTx-1301, uses Precision Timed Release to deliver dexmethylphenidate across the day in a once-daily tablet. The clinical-stage company's FDA application received a Complete Response Letter seeking manufacturing information.
Built around a multi-core delivery platform, Precision Timed Release (PTR) is designed to give CTx-1301 three timed releases of dexmethylphenidate in a once-daily tablet for ADHD. The company remains clinical-stage and conducts operations through its wholly owned subsidiary, Cingulate Therapeutics LLC (CTx). This is the company's lead ADHD program.
CTx-1301 entered FDA review for ADHD after adult and pediatric trials and other FDA-requested studies. The FDA issued a Complete Response Letter requesting specified chemistry, manufacturing, and controls information; Cingulate said the letter did not identify current clinical-safety or efficacy concerns.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 23, 2026 | Roth Capital | Target | $10 | $9 | ||
| May 19, 2026 | Roth Capital | Target | $11 | $10 | ||
| Nov 20, 2024 | Maxim Group | Upgrade | Hold | Buy |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $28.4M · Total debt $6.3M · Total assets $33.1M · Shareholders' equity $23.5M
- Revenue
- $0
- Operating income
- −$5.4M
- Net income
- −$5.9M
No dividends on record.
| Institutions27 holders · as of Mar 31, 2026 | 8.17% | 1.19M shares | |
| Insiders7 holders · as of Jun 8, 2026 | 1.78% | 259.3K shares | |
| Strategic holders1 holder · as of Mar 26, 2026 | 26.52% | 3.86M shares | |
| Otherremainder | 63.53% | 9.24M shares |
14.54M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Falcon Creek Capital Advisor LLCStrategic | 26.52% | 3.86M | 13Dfiled Mar 26, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 2.12% | 308,967 | 13Fas of Mar 31, 2026 |
Kestra Advisory Services, LLCInstitution | 0.96% | 140,000 | 13Fas of Mar 31, 2026 |
Peter J. WerthInsiderdirector | 0.81% | 117,449 | Form 4filed Feb 10, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.70% | 101,373 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 13, 2026 | Thomas Jeffrey Hargroves | director | +175,097 | $5.04 |
| Feb 6, 2026 | Matthew Brams | officer: EVP and Chief Medical Officer | +3,502 | $5.04 |
| Feb 6, 2026 | Shane J. Schaffer | director, officer: Chief Executive Officer | +12,256 | $5.04 |
| Feb 6, 2026 | Jennifer L. Callahan | officer: SVP and CFO | +8,755 | $5.04 |
| Feb 6, 2026 | Peter J. Werth | director | +35,019 | $5.04 |
- Novartis (ADR)
Reference-listed dexmethylphenidate XR therapy for ADHD
- Collegium Pharmaceutical
AZSTARYS in once-daily dexmethylphenidate ADHD therapy
- Takeda (ADR)
Vyvanse and Adderall XR in stimulant ADHD treatment
- Supernus Pharmaceuticals
Qelbree in once-daily ADHD treatment across age groups
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cingulate | $5.16 | +0.98% | $69.4M | — | — | — | — |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Collegium Pharmaceutical | $24.50 | +0.86% | $788.1M | 19.6 | 3.4 | 1.0 | +6.3% |
| Takeda (ADR) | $18.73 | +1.55% | $58.65B | 51.2 | 56.8 | 2.0 | +5.8% |
| Supernus Pharmaceuticals | $44.20 | +0.39% | $2.56B | — | 15.2 | 3.1 | +32.4% |
| Median | 24.5 | 16.3 | 2.6 | +6.0% |